Physician profile
Beth Ledvora
NPI 1104993161
$13,037.26
in general payments reported to CMS, 2019-2025
32 companies · $1,912 in 2025
The $1,912 reported for 2025 was more than what 89% of Psychiatry providers received nationally (typical 2025 total: $176).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,698 · 2020: $1,605 · 2021: $1,768 · 2022: $1,342 · 2023: $2,076 · 2024: $2,637 · 2025: $1,912.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $6,626.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $6,625.54 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $1,777.02 | 2021-2025 | |
| Lundbeck LLC | $1,146.80 | 2019-2025 | Rexulti |
| Allergan, INC. | $1,081.97 | 2019-2020 | |
| Vanda Pharmaceuticals INC. | $1,009.39 | 2019-2025 | Fanapt, Hetlioz |
| Neurocrine Biosciences, INC. | $988.85 | 2019-2025 | Ingrezza |
| Janssen Pharmaceuticals, INC | $971.16 | 2019-2025 | Spravato, Invega Sustenna, Invega Trinza |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $866.90 | 2020-2025 | Caplyta |
| Otsuka America Pharmaceutical, INC. | $772.26 | 2019-2025 | Rexulti |
| Eisai INC. | $411.82 | 2020-2022 | |
| Axsome Therapeutics, INC. | $402.17 | 2022-2025 | Auvelity, Sunosi |
| Alkermes, INC. | $383.10 | 2023-2025 | Aristada, Lybalvi |
| Takeda Pharmaceuticals U.S.A., INC. | $357.31 | 2019-2025 | Trintellix |
| Corium, LLC | $355.56 | 2022-2025 | Azstarys |
| Bausch Health US, LLC | $344.24 | 2019-2025 | Wellbutrin, Aplenzin |
| Teva Pharmaceuticals USA, INC. | $287.90 | 2019-2024 | Uzedy, Austedo Xr, Austedo |
Show all 32 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Sunovion Pharmaceuticals INC. | $243.84 | 2019-2022 | |
| Supernus Pharmaceuticals, INC. | $229.86 | 2021-2024 | Qelbree, Qelbree |
| Jazz Pharmaceuticals INC. | $214.35 | 2019-2025 | |
| Idorsia Pharmaceuticals US INC | $203.86 | 2022-2025 | Quviviq, Quviviq |
| Tris Pharma INC | $187.31 | 2023-2025 | Dyanavel Xr |
| Ironshore Pharmaceuticals INC. | $164.60 | 2019-2024 | Jornay Pm |
| Neos Therapeutics, Lp | $117.15 | 2019-2025 | Adzenys Xr-Odt |
| Adlon Therapeutics L.P. | $103.23 | 2020-2021 | |
| Almatica Pharma LLC | $94.32 | 2021-2024 | Loreev Xr, Sertraline Hcl |
| Shire North American Group INC | $89.45 | 2019 | |
| E.R. Squibb & Sons, L.L.C. | $74.33 | 2024-2025 | Cobenfy |
| Owp Pharmaceuticals, INC. | $37.89 | 2023-2025 | Subvenite, Lamotrigine |
| Noven Therapeutics, LLC | $34.16 | 2024 | Xelstrym, Secuado |
| Acadia Pharmaceuticals INC | $32.48 | 2019 | |
| Ortho Dermatologics, A Division of Bausch Health US, LLC | $22.32 | 2023 | Aplenzin |
| Neuronetics, INC. | $19.64 | 2019 | |
| Rhodes Pharmaceuticals L.P. | $12.02 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Beth Ledvora listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.